Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Erkes, Dan A.; Cai, Weijia; Sanchez, Ileine M.; Purwin, Timothy J.; Rogers, Corey; Field, Conroy O.; Berger, Adam C.; Hartsough, Edward J.; Rodeck, Ulrich; Alnemri, Emad S.; Aplin, Andrew E.

doi:10.1158/2159-8290.cd-19-0672

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + …